Pharsight

Drugs that contain Dacomitinib

1. Vizimpro patents expiration

VIZIMPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7772243 PFIZER 4-phenylamino-quinazolin-6-yl-amides
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883 PFIZER 4-phenylamino-quinazolin-6-yl-amides
May, 2025

(1 year, 14 days from now)

US10596162 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(1 year, 9 months from now)

US10603314 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(1 year, 9 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-206) Sep 27, 2025
Orphan Drug Exclusivity(ODE-213) Sep 27, 2025
New Chemical Entity Exclusivity(NCE) Sep 27, 2023

NCE-1 date: 27 September, 2022

Market Authorisation Date: 27 September, 2018

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a u...

Dosage: TABLET;ORAL

More Information on Dosage

VIZIMPRO family patents

Family Patents